Home › Noble Financial Reaffirms "Buy" Rating for BioCryst Pharmaceuticals, Inc.
 

Keywords :   


Noble Financial Reaffirms "Buy" Rating for BioCryst Pharmaceuticals, Inc.

2016-02-28 04:00:20| Biotech - Topix.net

's stock had its "buy" rating restated by Noble Financial in a research report issued to clients and investors on Friday, Analyst Ratings Network.com reports. They presently have a $8.00 target price on the biotechnology company's stock.

Tags: inc buy rating financial

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
16.05CFTC charges Agridime and its co-founders with a fraudulent cattle scheme
16.05Baleage: Advantageous for first cutting hay
16.05Hydrosome Labs Technology Poised to Usher in New Era of Precision Fermentation
16.05Tools for environmental challenge
16.05Hubbl integrates global streaming apps with Amdocs
16.05Croda Beauty Launches New Ceramide Range
16.05Doves New Bond Strength Range Contains Proprietary Bio-Protein Care and Peptides
16.05Mount Sinai Awarded $6.6 Million from National Institutes of Health to Investigate Treatment ...
More »